福多司坦对稳定期慢阻肺患者炎症和氧化应激状态的影响被引量：14

Effects of fudosteine on the inflammation and oxidative stress in patients with stable chronic obstructive pulmonary disease

下载PDF

导出

摘要目的观察福多司坦对稳定期慢性阻塞性肺疾病（COPD）的临床疗效及其对炎症和氧化应激状态的影响。方法选择60例稳定期COPD患者为研究对象，随机分为福多司坦组（n=30）和对照组（n=30），对照组采取包括吸入长效支气管扩张剂、糖皮质激素／长效p：受体激动剂联合制剂和家庭氧疗等常规治疗，福多司坦组在常规治疗的基础上口服福多司坦片，连续服用3个月。治疗前后进行CAT评分、肺功能和呼吸阻抗检查，并测定血清IL-8、IL-17、肿瘤坏死因子（TNF）ot、血清丙二醛（MDA）和超氧化物歧化酶（SOD）水平。结果福多司坦组患者第一秒用力呼气容积（FEV，）、用力肺活量（FVC）较治疗前升高，而R5、R20和CAT评分较治疗前明显降低（P〈0．05），肺功能和症状改善情况明显优于对照组（P〈0．05）。2组患者治疗后血清炎症指标IL-8、IL-17和TNF-α较治疗前均有降低。福多司坦组血清IL-8、IL-17和TNF-α治疗后下降程度明显高于对照组（P〈0．05）。福多司坦组患者血清MDA较治疗前显著降低，SOD水平治疗后明显升高（P〈0．05）；而对照组患者治疗前后血清MDA和SOD水平，差异无统计学意义。结论福多司坦抑制炎症反应和氧化应激状态，能够改善稳定期COPD患者的临床症状和肺功能。 Objective To evaluate the clinical efficacy of fudosteine to treat stable chronic obstructive pulmonary disease （COPD） and explore fudosteine effects on inflammation and oxidative stress in COPD patients. Methods A to- tal of 60 patients with stable COPD were selected and randomly divided into a control group （n = 30） and a fudosteine group （ n = 30）. Patients in the control group received conventional treatment including inhaling long acting - bronchodi- lators alone or combined with corticosteroids as well as oxygen therapy at home. In contrast, those in the fudosteine group were treated with fudosteine for three consecutive months in addition to routine therapy. All the patients underwent the COPD assessment test （CAT） and were examined for their pulmonary function and resistance before and after treatment. Meanwhile, their levels of serum interleukin - 8 （ IL - 8 ）, interleukin - 17 （ IL - 17 ） and tumor necrosis factor - ct （TNF- ct） and serum malondialdehyde （MDA） and superoxide dismutase （SOD） were determined. Results After treatment, the fudosteine group presented increases in forced expiratory volume in one second （FEV1） and forced vital capacity （FVC） but decreases in pulmonary resistance at 5 Hz and 20 Hz and CAT scores compared with its levels before treatment. Meanwhile, the fudosteine group showed great improvement in pulmonary function and symptoms compared with the control group （all P 〈 O. 05 ）. After treatment, both groups demonstrated significant reduced amounts of serum IL - 8, IL - 17 and TNF -α compared with their levels after treatment （ all P 〈 0.05 ）. Meanwhile, the fudosteine group presented marked decreases in the amounts of serum IL - 8, IL - 17 and TNF -α than the control group （ P 〈 0.05 ）. After treatment, the fudosteine group produced a significant decreased amount of serum MDA and a remarkable increased quantity of serum SOD than its levels before treatment, whereas no obvious change in serum MDA and SOD was observedi